DIPRIVAN (Propofol) Injectable Emulsion, USP is the #1 prescribed propofol in the U.S.¹

DIPRIVAN is the only propofol containing EDTA

EDTA (Ethylenediaminetetraacetic Acid or Disodium Edetate) is an antimicrobial retardant. This formulation of propofol with EDTA is exclusively available from Fresenius Kabi.

DIPRIVAN medication types

DIPRIVAN product features

  • Contains EDTA (Ethylenediaminetetraacetic Acid)
  • Sulfite free
  • Benzyl alcohol free
  • Vial stoppers do not contain natural rubber latex
  • Bar coded
  • Spike-and-hang vial (50 mL and 100 mL)

Use our infusion
rate calculator

Simplify calculations for patient sedation. Save a link to your mobile device.

Indications and Dosing

Summary of Dosage Guidelines: Dosages and rates of administration in the following table should be individualized and titrated to clinical response. Safety and dosing requirements for induction of anesthesia in pediatric patients have only been established for children 3 years of age or older. Safety and dosing requirements for the maintenance of anesthesia have only been established for children 2 months of age and older. (See DOSAGE AND ADMINISTRATION in Full Prescribing Information)

Induction of General Anesthesia

Patients ≥3 years of age

Healthy Adults Less Than 55 Years of Age:

40 mg every 10 seconds until induction onset (2 to 2.5 mg/kg).

Elderly, Debilitated, or ASA-PS III or IV Patients:

20 mg every 10 seconds until induction onset (1 to 1.5 mg/kg).

Cardiac Anesthesia:

20 mg every 10 seconds until induction onset (0.5 to 1.5 mg/kg).

Neurosurgical Patients:

20 mg every 10 seconds until induction onset (1 to 2 mg/kg).

Pediatric Patients—healthy, from 3 years to 16 years of age:

2.5 to 3.5 mg/kg administered over 20 to 30 seconds.

(see PRECAUTIONS, Pediatric Use and CLINICAL PHARMACOLOGY, Pediatrics in Full Prescribing Information)

Maintenance of General Anesthesia—Infusion

Patients ≥2 months of age

Healthy Adults Less Than 55 Years of Age:

100 to 200 mcg/kg/min (6 to 12 mg/kg/h).

Elderly, Debilitated, or ASA-PS III or IV Patients:

50 to 100 mcg/kg/min (3 to 6 mg/kg/h).

Cardiac Anesthesia:

Most patients require:

Primary DIPRIVAN Injectable Emulsion with Secondary Opioid—100 to 150 mcg/kg/min

Low-Dose DIPRIVAN Injectable Emulsion with Primary Opioid—50 to 100 mcg/kg/min

(see DOSAGE AND ADMINISTRATION, Table 4 in Full Prescribing Information)

Neurosurgical Patients:

100 to 200 mcg/kg/min (6 to 12 mg/kg/h).

Pediatric Patients—healthy, from 3 years to 16 years of age:

125 to 300 mcg/kg/min (7.5 to 18 mg/kg/h).

Following the first half hour of maintenance, if clinical signs of light anesthesia are not present, the infusion rate should be decreased.

(see PRECAUTIONS, Pediatric Use and CLINICAL PHARMACOLOGY, Pediatrics in Full Prescribing Information)

Maintenance of General Anesthesia—Intermittent Bolus

Adults only

Healthy Adults Less Than 55 Years of Age:

Increments of 20 to 50 mg as needed.

Initiation of MAC Sedation

Adults only

Healthy Adults Less Than 55 Years of Age:

Slow infusion or slow injection techniques are recommended to avoid apnea or hypotension. Most patients require an infusion of 100 to 150 mcg/kg/min (6 to 9 mg/kg/h) for 3 to 5 minutes or a slow injection of 0.5 mg/kg over 3 to 5 minutes followed immediately by a maintenance infusion.

Elderly, Debilitated, Neurosurgical, or ASA-PS III or IV Patients:

Most patients require dosages similar to healthy adults. Rapid boluses are to be avoided (see warnings in Full Prescribing Information)

Maintenance of MAC Sedation

Adults only

Healthy Adults Less Than 55 Years of Age:

A variable rate infusion technique is preferable over an intermittent bolus technique. Most patients require an infusion of 25 to 75 mcg/kg/min (1.5 to 4.5 mg/kg/h) or incremental bolus doses of 10 mg or 20 mg.

Elderly, Debilitated, Neurosurgical, or ASA-PS III or IV Patients:

Most patients require 80% of the usual adult dose. A rapid (single or repeated) bolus dose should not be used (see warnings in Full Prescribing Information)

Initiation and Maintenance of ICU Sedation in Intubated, Mechanically Ventilated Adult Patients

Because of the residual effects of previous anesthetic or sedative agents, in most patients the initial infusion should be 5 mcg/kg/min (0.3 mg/kg/h) for at least 5 minutes. Subsequent increments of 5 to 10 mcg/kg/min (0.3 to 0.6 mg/kg/h) over 5 to 10 minutes may be used until desired clinical effect is achieved. Maintenance rates of 5 to 50 mcg/kg/min (0.3 to 3 mg/kg/h) or higher may be required. Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see warnings in Full Prescribing Information)

Evaluation of clinical effect and assessment of CNS function should be carried out daily throughout maintenance to determine the minimum dose of DIPRIVAN Injectable Emulsion required for sedation.

The tubing and any unused portions of DIPRIVAN Injectable Emulsion should be discarded after 12 hours because DIPRIVAN Injectable Emulsion contains no preservatives and is capable of supporting growth of microorganisms (see WARNINGS and DOSAGE AND ADMINISTRATION in Full Prescribing Information).

Combined Sedation and Regional Anesthesia

Adults only

See PRECAUTIONS in Full Prescribing Information

Warnings and Precautions

See PRECAUTIONS, WARNINGS, and ADVERSE REACTIONS in Full Prescribing Information

Calculation Information

The patient's body weight and desired dosage determine the infusion rate. The lipid load and caloric intake can be determined from the infusion rate.

Dosage (mcg/kg/min) × Weight (kg) × 60 (min/hr) ÷ 10,000 (mcg/mL)
= Infusion rate (mL/h)
Infusion rate (mL/h) × 0.1 g fat/mL
= Lipid intake (g/h)
Infusion rate (mL/h) × 1.1 kcal/mL
= Caloric intake (kcal/h)

Complete dosing information, including other indications, is in the Full Prescribing Information.

DISCLAIMER. By using this resource, you agree to the following: this Infusion Rate Calculator is being provided "AS IS" and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Fresenius Kabi USA makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Fresenius Kabi USA, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.

Reference
  1. Diprivan data on file.